fbpx

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

noticia |

Tandstad T., Ståhl O., Håkansson U., Dahl O., Haugnes H.S., Klepp O.H., Langberg C.W., Laurell A., Oldenburg J., Solberg A., Söderström K., Cavallin-Ståhl E., Stierner U., Wahlquist R., Wall N., Cohn-Cedermark G.

Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2014 25:11 (2167-2172)

BACKGROUND: SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results.PATIENTS AND METHODS: In a prospective, binational, population-based risk-adapted treatment protocol, 517 Norwegian and Swedish patients with CS I nonseminoma received one course of adjuvant BEP. Patients with lymphovascular invasion (LVI) in the primary testicular tumor were recommended one course of adjuvant BEP. Patients without LVI could choose between surveillance and one course of adjuvant BEP. Data for patients receiving one course of BEP are presented in this study.RESULTS: At a median follow-up of 7.9 years, 12 relapses have occurred, all with IGCCC good prognosis. The latest relapse occurred 3.3 years after adjuvant treatment. The relapse rate at 5 years was 3.2% for patients with LVI and 1.6% for patients without LVI. Five-year cause-specific survival was 100%.CONCLUSIONS: The updated and expanded results confirm a low relapse rate following one course of adjuvant BEP in CS I nonseminoma. One course of adjuvant BEP should be considered a standard treatment in CS I nonseminoma with LVI. For patients with CS I nonseminoma without LVI, one course of adjuvant BEP is also a treatment option.

Valorar

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...